A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to advance its lead KRAS inhibitor into phase 3 studies. D3 Bio saw previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback